Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec 26:18:241-252.
doi: 10.1016/j.csbj.2019.12.006. eCollection 2020.

Machine learning applications in drug development

Clémence Réda  1   2 , Emilie Kaufmann  3 , Andrée Delahaye-Duriez  1   4   5
Affiliations
Review

Machine learning applications in drug development

Clémence Réda et al. Comput Struct Biotechnol J. .

Abstract

Due to the huge amount of biological and medical data available today, along with well-established machine learning algorithms, the design of largely automated drug development pipelines can now be envisioned. These pipelines may guide, or speed up, drug discovery; provide a better understanding of diseases and associated biological phenomena; help planning preclinical wet-lab experiments, and even future clinical trials. This automation of the drug development process might be key to the current issue of low productivity rate that pharmaceutical companies currently face. In this survey, we will particularly focus on two classes of methods: sequential learning and recommender systems, which are active biomedical fields of research.

Keywords: Adaptive clinical trial; Bayesian optimization; Collaborative filtering; Drug discovery; Drug repurposing; Multi-armed bandit.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Representation of the four stages of drug development, along with Phase IV, which occurs after the start of drug marketing.
Fig. 2
Fig. 2
Evolution of average development cost in a cohort of 12 major phamaceutical labs, in millions of dollars, between 2010 and 2018 .
Fig. 3
Fig. 3
A K-armed bandit, where the learning agent interacts with its environment by sequentially selecting arms, and updating its strategy using the observations it obtains.
Fig. 4
Fig. 4
Generative Adversarial Networks for Drug Discovery. A Generative Adversarial Network is a set of two neural networks, the Generator and the Discriminator. These two networks are trained at the same time.
Fig. 5
Fig. 5
Randomized Clinical Trial (RCT) versus Adaptive Clinical Trial (ACT) for Phase III. A Randomized Clinical Trial (RCT) “randomly” assign patients to treatment arms (ensuring balance of covariates of interest) before testing, whereas an Adapted Clinical Trial sequentially assigns patients to treatment arms according to previous testing results.
See this image and copyright information in PMC

References

    1. Eliopoulos H., Giranda V., Carr R., Tiehen R., Leahy T., Gordon G. Phase 0 trials: an industry perspective. Clin Cancer Res. 2008;14(12):3683–3688. - PubMed
    1. Xue H., Li J., Xie H., Wang Y. Review of drug repositioning approaches and resources. Int J Biol Sci. 2018;14(10):1232. - PMC - PubMed
    1. Schuhmacher A., Gassmann O., Hinder M. Changing R&D models in research-based pharmaceutical companies. J Transl Med. 2016;14(1):105. - PMC - PubMed
    1. Khanna I. Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discovery Today. 2012;17(19–20):1088–1102. - PubMed
    1. Hwang T.J., Carpenter D., Lauffenburger J.C., Wang B., Franklin J.M., Kesselheim A.S. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Internal Med. 2016;176(12):1826–1833. - PubMed